Argus

Analysts at Argus Research turned bullish on Bioverativ Inc (NASDAQ: BIVV) as the company could establish itself as a profitable biotech within the hemophilia and blood disorders space. The firm's Jasper Hellweg upgraded Bioverativ's stock from Hold to Buy. Bioverativ was spun-off by Biogen...

Argus said in a Wednesday note that Intuit Inc. (NASDAQ: INTU) shares continue to trade at attractive valuation despite a strong run the past two years. Accordingly, the firm initiated coverage of Intuit at Buy with a $165 price target. Analyst Jim Kelleher believes the rise of entrepreneurial...

Initiating coverage of DowDuPont Inc (NYSE: DWDP), Argus said in a note Tuesday it believes the management guidance for $3 billion in cost synergies and $1 billion in growth synergies over the next 18 months are conservative. Therefore, the firm expects these two metrics to be raised going...

Argus upgraded shares of Harsco Corporation (NYSE: HSC) from Hold to Buy, with a price target of $21. The price target represents roughly 18 percent upside from the stock's closing of $17.85 on Thursday. Analysts David Coleman stated that the industrial services and engineered products...

Argus initiated coverage of Lam Research Corporation (NASDAQ: LRCX) with a Buy rating and $196 price target for the shares, as it believes the company would benefit from demand growth for NAND and DRAM memory chips used in artificial intelligence, the Internet of Things, cloud computing and...

Argus said in a note that it sees bullish growth outlook for Incyte Corporation (NASDAQ: INCY) given its solid late-stage pipeline and key strategic R&D partnerships with companies such as Merck & Co., Inc. (NYSE: MRK), Novartis AG (ADR)(NYSE: NVS), Bristol-Myers Squibb Co (NYSE: BMY)...

Argus said in a note released Friday that the recent weakness in Sanofi SA (ADR) (NYSE: SNY) shares offers a buying opportunity. The firm noted that the company's shares fell 2.1 percent over the second quarter compared to a 1-percent increase in the MSCI EAFE Index. The firm has a Buy rating...

It’s taking time, but three days after Gilead Sciences, Inc. (NASDAQ: GILD) announced its acquisition of Kite Pharma Inc (NASDAQ: KITE), the Street seems to be deciding it’s a good thing. Gilead’s stock traded up a modest 2.5 percent and three analysts reiterated Hold ratings...

Argus said in a note on Wednesday that the recent weakness in GlaxoSmithKline plc (ADR) (NYSE: GSK) shares offers a buying opportunity. The firm noted that as against the 1 percent gain by the broader market, the company's shares have fallen 8 percent over the past quarter. As such, the firm...

Analysts at Argus Research no longer hold a bullish view on the pizza delivery chain Domino's Pizza, Inc. (NYSE: DPZ) and suggest instead owning shares of the fast food giant McDonald's Corporation (NYSE: MCD). Argus' John Staszak downgraded Domino's stock from a Buy rating to a Hold, the first...